Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
November 15 Product: Revuforj Indication: Relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene translocation Syndax Pharmaceuticals Revuforj (revumenib) on Friday became the markets first menin inhibitor for relapsed or refractory acute leukemia when the FDA cleared it for use in adult or pediatric patients carrying a translocation mutation in the lysine methyltransferase 2A ( KMT2A ) gene
it is the most readily absorbed
"The advice was it had been considered under S2 (as not prohibited) and therefore effectively S0 did not come into play," he said
In addition, andrographolide has a protective effect on APAP-induced hepatotoxicity both in vivo and in vitro (Yan et al., 2018)
US$ 23.24
US$ 25.58
US$ 20.75
US$ 20.48
US$ 25.87
US$ 27.86
US$ 20.37
US$ 24.38
